Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs
Valentina L. Kouznetsova, Aidan Zhang, Mark A. Miller, Mahidhar Tatineni, Jerry P. Greenberg, Igor F. Tsigelny
Abstract
The SARS-CoV-2 virus Spike (S) protein binds to an angiotensin-converting-enzyme 2 receptor (ACE2) on the surface of cells to allow viral DNA entry. Given the plenitude of FDA-approved antiviral drugs, we aimed to screen those that may be repurposed for treating SARS-CoV-2 infections.
Topics & Concepts
RepurposingDrug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Spike ProteinCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakAngiotensin-converting enzyme 2Spike (software development)PharmacologyApproved drugCoronavirusDrugViral entryMedicineBiologyVirusViral replicationComputer scienceInternal medicineInfectious disease (medical specialty)DiseaseOutbreakEcologySoftware engineeringSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Outbreaks Research